Hemoglobin A1c Levels and Aortic Arterial Stiffness: The Cardiometabolic Risk in Chinese (CRC) Study

Citation
Liang, Jun, Na Zhou, Fei Teng, Caiyan Zou, Ying Xue, Manqing Yang, Huaidong Song, and Lu Qi. 2012. Hemoglobin A1c levels and aortic arterial stiffness: The Cardiometabolic Risk in Chinese (CRC) study. PLoS ONE 7(8):e38485.

Published Version
doi:10.1371/journal.pone.0038485

Permanent link
http://nrs.harvard.edu/urn-3:HUL.InstRepos:10352040

Terms of Use
This article was downloaded from Harvard University’s DASH repository, and is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA

Share Your Story
The Harvard community has made this article openly available. Please share how this access benefits you. Submit a story.

Accessibility
Hemoglobin A1c Levels and Aortic Arterial Stiffness: The Cardiometabolic Risk in Chinese (CRC) Study

Jun Liang1,2,*, Na Zhou1,*, Fei Teng1, Caiyan Zou1, Ying Xue1, Manqing Yang1, Huaidong Song4, Lu Qi2,3 *

1 Department of Endocrinology, the Central Hospital of Xuzhou, Affiliated Hospital of Southeast University, Xuzhou Clinical School of Xuzhou Medical College, Xuzhou, Jiangsu, China, 2 Department of Nutrition, Harvard School of Public Health, Boston, Massachusetts, United States of America, 3 Channing Laboratory, Department of Medicine, Brigham and Women’s Hospital and Harvard Medical School, Boston, Massachusetts, United States of America, 4 Ruijin Hospital, State Key Laboratory of Medical Genomics, Molecular Medical Center, Shanghai Institute of Endocrinology, Shanghai Jiao Tong University School of Medicine, Shanghai, China

Abstract

Objective: The American Diabetes Association (ADA) recently published new clinical guidelines in which hemoglobin A1c (HbA1c) was recommended as a diagnostic test for diabetes. The present study was to investigate the association between HbA1c and cardiovascular risk, and compare the associations with fasting glucose and 2-hour oral glucose tolerance test (2 h OGTT).

Research Design and Methods: The study samples are from a community-based health examination survey in central China. Carotid-to-femoral pulse wave velocity (cPWV) and HbA1c were measured in 5,098 men and women.

Results: After adjustment for age, sex, and BMI, the levels of HbA1c were significantly associated with an increasing trend of cPWV in a dose-dependent fashion (P for trend < 0.0001). The associations remained significant after further adjustment for blood pressure, heart rate, and lipids (P = 0.004), and the difference in cPWV between the highest and the lowest quintiles of HbA1c was 0.31 m/s. Fasting glucose and 2 h OGTT were not associated with cPWV in the multivariate analyses. HbA1c showed additive effects with fasting glucose or 2 h OGTT on cPWV. In addition, age and blood pressure significantly modified the associations between HbA1c and cPWV (P for interactions < 0.0001 for age; and = 0.019 for blood pressure). The associations were stronger in subjects who were older (≥ 60 y; P for trend = 0.004) and had higher blood pressure (≥ 120 [systolic blood pressure]/80 mmHg [diastolic blood pressure]; P for trend = 0.028) than those who were younger and had lower blood pressure (P for trend > 0.05).

Conclusions: HbA1c was related to high cPWV, independent of conventional cardiovascular risk factors. Senior age and high blood pressure might amplify the adverse effects of HbA1c on cardiovascular risk.

Introduction

Recently, the American Diabetes Association (ADA) published new clinical guidelines in which hemoglobin A1c (HbA1c) level, in addition to fasting glucose and 2-hour oral glucose tolerance test (2 h OGTT), was recommended as a diagnostic test for diabetes [1]. HbA1c is a marker of long-term glycemic exposure, reflecting an average blood glucose level over 2–3 month period of time. The cut-points for the diagnosis of diabetes are based on the presence of long-term complications. However, the current evidence for the ADA recommendation is largely from the studies on the relations between HbA1c and microvascular diseases especially retinopathy [2]. Even though macrovascular disease complications are more prevalent and the primary causes for mortality in diabetes, the data about the associations between HbA1c and macrovascular risk are surprisingly lacking.

Arterial stiffness is an established marker for early-stage atherosclerosis. Among various approaches to assess early-stage arterial stiffness, carotid-to-femoral pulse wave velocity (cPWV) has been widely recognized a gold standard method [3], and independently associated with cardiovascular outcomes such as myocardial infarction, heart failure, and mortality [4–7]. Some recent studies associated HbA1c with arterial stiffness measured by cPWV in patients with type 2 diabetes [8] and hemodialysis [9]. Studies examining the relation between HbA1c and arterial stiffness in the general population are sparse. In addition, fasting and post-challenge glucose concentrations were also related to accelerated stiffening of the elastic arteries that contributes to the excessive cardiovascular risk [7,10,11]. The effects of various glucose exposures are not perfectly concordant and may be independent [12]. However, little is known about the relative influence of HbA1c and fasting and post-challenge glucose on cardiovascular risk.

The aim of this study was to examine the associations between HbA1c as the marker of long-term glucose exposure and cPWV...
in a large sample of Chinese adults, and to compare with the associations of fasting glucose and 2 h OGTT. We also assessed the modification effects of age, sex, obesity and blood pressure on the relations between glucose exposures and aortic arterial stiffness.

**Materials and Methods**

**Study population**

In the Cardiometabolic Risk in Chinese (CRC) Study, we performed a community-based health examination survey for 6,431 individuals (18–93 y) who were randomly selected from residents living in the urban area of Xuzhou, China, in 2009. Written consents were obtained from all the participants. The study was reviewed and approved by the ethics committee of the Central Hospital of Xuzhou, China. Among the participants, 5,514 individuals were measured for both cfPWV and HbA1c. For the present study, we excluded subjects with history of diabetes, or fasting glucose ≥7.0 mmol/L, and/or 2 h OGTT ≥11.1 mmol/L, and/or HbA1c≥6.5% [12,13]. In total 5,098 men and women were included in the final analyses. There was not significant difference in age and anthropometrics between individuals who were included and those who were not included in the analyses.

**Assessment of Carotid-to-femoral PWV**

Carotid-to-femoral PWV in subjects at rest was measured using Complior device (Artech-Medical, Pantin, France) that allows pulse wave recording and automatic calculation of cfPWV with 2 transducers. The operator recorded in succession the right carotid and femoral waveforms. cfPWV is calculated as the distance between the two recording sites divided by the time delay between the feet of the two waveforms at each site. Sixteen cfPWVs were measured for each participant. After removing 6 extreme values (3 maximum and 3 minimum), an average value of cfPWV was calculated.

**Assessment of biomarkers and covariates**

Venous blood sample was drawn from all subjects after an overnight fast (10 h). The blood was transferred into glass tubes and allowed to clot at room temperature. Immediately following clotting serum was separated by centrifugation for 15 min at 3,000 rpm. HbA1c was measured using high performance liquid chromatography (HPLC; HLC-723G7 hemoglobin HPLC analyzer, Tosoh Corp.) according to the standardized method. Participants with no history of diabetes underwent a 75-g oral glucose tolerance test (OGTT). Blood samples were drawn at 120 minutes after the glucose or carbohydrate load. Plasma glucose was measured using the hexokinase glucose-6-phosphate dehydrogenase method (Type 7600; Hitachi Ltd., Tokyo, Japan). The levels of total cholesterol, triglyceride, high-density lipoprotein cholesterol (HDL-C), and low-density lipoprotein cholesterol (LDL-C) were determined enzymatically using an autoanalyzer (Type 7600; Hitachi Ltd., Tokyo, Japan).

Height was measured to the nearest 0.5 cm without shoes and body weight was measured to the nearest 100 grams without shoes. Body mass index (BMI) was calculated as weight (in kilograms) divided by height (in meters) squared. Waist circumference was measured at the mid-point between the lowest rib margin and the iliac crest. Blood pressure was measured at the same time of cfPWV measurement after the subject had rested for at least 5 minutes with a mercury manometer by doctors. The subject’s arm was placed at the heart level. Three measurements, 60 seconds apart, were taken. Systolic blood pressure (SBP) was defined as the average of the three SBP readings. Diastolic blood pressure (DBP) was defined as the average of the three DBP readings. The mean arterial pressure (MAP) was calculated as 2/3(DBP) + 1/3(SBP).

**Statistical analyses**

A linear regression model was used to evaluate associations between glucose exposures (HbA1c, fasting glucose, and 2 h OGTT) and cfPWV, adjusting for covariates. Glucose exposures were analyzed in quintiles. cfPWV was analyzed as the dependent variable, and levels of HbA1c, fasting glucose, or 2 h OGTT were analyzed as the independent variables. Tests for linear trend were calculated by assigning median value for each quintile of intake and treated as continuous variables. We adjusted for the potential confounding variables: age, sex, BMI, MAP, heart rate and lipids (total cholesterol, triglyceride, HDL-C and LDL-C). The effect modifications of age (<40, 40–59, ≥60 y), BMI (<25, ≥25 kg/m²), sex, and blood pressure (low vs high by the cutoffs of SBP=120 mmHg and DBP=80 mmHg) were tested by introduction of the cross-products of the tested variables and HbA1c into the models. We used the SAS statistical package for all analyses (Version 9.1, SAS Institute, Cary, NC). All P-values are two-sided.

**Results**

In total 5,098 men and women were included in the analyses. Table 1 presents the characteristics of the participants by the quintiles of HbA1c. Individuals with higher HbA1c had higher SBP, BMI, waist circumference, fasting glucose, 2 h OGTT, total cholesterol, triglyceride, and LDL-C, but lower HDL-C than those who were with lower HbA1c.

We first examined the associations between three measures of glucose exposure (HbA1c, fasting glucose and 2 h OGTT) and cfPWV (Table 2). In the models adjusting for age, sex and BMI, all the three measures were significantly associated with increasing trend of cfPWV (P<0.0001). When MAP was further adjusted, the associations for fasting glucose (P = 0.01), 2 h OGTT (P = 0.04), and HbA1c (P = 0.005) remained significant. When other covariates including heart rate, total cholesterol, TG, HDL-C and LDL-C were further adjusted, the associations for fasting glucose and 2 h OGTT were attenuated to be not significant, while the association for HbA1c remained significant (P = 0.004). In the fully-adjusted model, the difference in cfPWV between the highest and the lowest quintiles of HbA1c was 0.31 m/s.

According to the ADA recommendation [12], we defined ‘prediabetes’ by the cutoffs of the three glucose exposures, i.e. impaired fasting glucose (IFG, fasting glucose 5.6–6.9 mmol/L), impaired glucose tolerance (IGT, 2 h OGTT 7.8–11.0 mmol/L), and high HbA1c (5.7–6.4%) to represent an increased risk of diabetes but without fulfilling the criteria of diagnosis. The prevalence of IFG, IGT, and high HbA1c in this non-diabetic population were 12%, 14.3%, and 14.8%; respectively. The differences in cfPWV between individuals with IFG, IGT and high HbA1c and those without these abnormalities were 0.97, 1.08 and 0.92 m/s (P<0.0001; Figure 1).

We then examined the additive effects of HbA1c with fasting glucose and 2 h OGTT on cfPWV (Figure 2). In the analyses adjusting for age, sex, and BMI, as compared with individuals with fasting glucose <5.6 mmol/L and HbA1c <5.7%, those with high HbA1c only, with IFG only, and with both IFG and high HbA1c had 0.28 (P = 0.03), 0.27 (P = 0.015) and 0.48 m/s (P = 0.0003) higher cfPWV. Similarly, as compared with individuals with 2 h OGTT <7.8 mmol/L and HbA1c <5.7%, those with high HbA1c only, with IGT only, and with both IGT and high HbA1c had 0.18 (P = 0.10), 0.28 (P = 0.008) and 0.44 m/s (P = 0.0001).
higher cfPWV. Further adjustment for other covariates did not materially change the results. Our data also indicate that individuals of both high HbA1c and IFG or IGT had significantly higher levels of cfPWV compared with those who only had high HbA1c (p = 0.036 and 0.03; respectively; or those only had IFG (p = 0.02); or those only had IGT (p = 0.04).

Pulse wave velocity is strongly associated with age and blood pressure, and is also related to sex and BMI [14–16]. Therefore, we examined whether these variables modified the relation between HbA1c and cfPWV. We found significant interactions between HbA1c and age (40, 40–59, 60 y; P <0.0001) and blood pressure (low vs high by the cutoffs SBP ≤120 mmHg and/ or DBP ≤80 mmHg; P <0.0001).

Table 1. Clinical characteristics of the participants by HbA1c levels.

| Variables                              | HbA1c in quintiles | P value |
|----------------------------------------|--------------------|---------|
|                                        | Q1                 | Q2      | Q3      | Q4      | Q5      |
|                                        | <5.06              | 5.06–5.15| 5.16–5.33| 5.34–5.52| 5.53–6.49|
| N of participants                      | 1,181              | 1,043   | 1,068   | 772     | 1,034   |
| Age, years                             | 43±10              | 46±12   | 49±12   | 52±13   | 56±13   | <0.0001|
| Systolic blood pressure, mmHg          | 122±16             | 123±16  | 125±16  | 128±16  | 133±18  | <0.0001|
| Diastolic blood pressure, mmHg         | 78±11              | 78±11   | 79±11   | 81±11   | 82±12   | <0.0001|
| Heart rate, bpm                        | 71±9               | 70±11   | 70±10   | 70±10   | 70±11   | 0.35    |
| Waist circumference, cm                | 82.6±9.7           | 83.7±9.9| 86.1±9.4| 87.6±9.4| 90.7±9.1| <0.0001|
| Body mass index, kg/m²                 | 23.6±3.0           | 24.0±3.1| 24.6±2.9| 25.2±3.0| 26.2±3.2| <0.0001|
| >25 kg/m²                              | 29.7%              | 34%     | 41.5%   | 52.6%   | 60.3%   | <0.0001|
| Men, %                                 | 55%                | 56.1%   | 59.7%   | 56.6%   | 54.3%   | 0.1     |
| Biochemical measures                   |                    |         |         |         |         |         |
| Glucose, mmol/L                        | 4.79±0.41          | 4.88±0.38| 4.99±0.45| 5.07±0.44| 5.43±0.62| <0.0001|
| 2h OGTT, mmol/L                        | 5.57±1.19          | 5.76±1.22| 6.00±1.26| 6.42±1.39| 7.31±1.71| <0.0001|
| Total cholesterol, mmol/L              | 4.75±0.83          | 4.89±0.81| 5.11±0.90| 5.17±0.96| 5.33±0.94| <0.0001|
| Triglyceride, mmol/L                   | 1.33±1.22          | 1.37±1.03| 1.59±1.58| 1.69±1.50| 1.88±1.78| <0.0001|
| HDL-C, mmol/L                          | 1.29±0.31          | 1.26±0.30| 1.25±0.30| 1.21±0.29| 1.19±0.28| <0.0001|
| LDL-C, mmol/L                          | 2.74±0.7           | 2.94±0.69| 3.08±0.81| 3.16±0.75| 3.26±0.81| <0.0001|

Abbreviations: HDL-C, high density lipoprotein cholesterol; LDL-C, low density lipoprotein cholesterol; OGTT, oral glucose tolerance test; bpm, beats per minute.

Data are mean ± standard deviations for the continuous variables and percentage for the categorical variables.

Linear regression model was used to test trend for continuous variables; chi² test was used for the categorical variables.

doi:10.1371/journal.pone.0038485.t001

Table 2. Associations of fasting glucose, 2h OGTT, and HbA1c with cfPWV (m/s).

| Models                               | Fasting glucose                        | 2h OGTT                              | HbA1c                                |
|--------------------------------------|----------------------------------------|--------------------------------------|--------------------------------------|
|                                      | Age, sex, and BMI adjusted              | Further adjusted for blood pressure   | Further adjusted for other covariates*|
|                                      | 10.49 (0.05)                           | 10.62 (0.05)                         | 10.57 (0.06)                         |
|                                      | 10.65 (0.05)                           | 10.71 (0.05)                         | 10.56 (0.06)                         |
|                                      | 10.57 (0.05)                           | 10.58 (0.05)                         | 10.45 (0.06)                         |
|                                      | 10.69 (0.05)                           | 10.64 (0.05)                         | 10.48 (0.06)                         |
|                                      | 11.02 (0.05)                           | 10.86 (0.05)                         | 10.69 (0.06)                         |
|                                      | <0.0001                                | 0.01                                 | 0.44                                 |
|                                      | Further adjusted for other covariates*  | Further adjusted for blood pressure   | Further adjusted for other covariates*|
|                                      | 10.57 (0.06)                           | 10.70 (0.05)                         | 10.56 (0.06)                         |
|                                      | 10.56 (0.06)                           | 10.60 (0.06)                         | 10.56 (0.06)                         |
|                                      | 10.45 (0.06)                           | 10.64 (0.05)                         | 10.44 (0.06)                         |
|                                      | 10.69 (0.06)                           | 10.87 (0.06)                         | 10.52 (0.07)                         |
|                                      | 0.56                                   | 0.04                                 | 0.56                                 |
|                                      | HbA1c                                  | Age, sex, and BMI adjusted            | Further adjusted for blood pressure   |
|                                      | Age, sex, and BMI adjusted              | Further adjusted for other covariates*|
|                                      | 10.59 (0.05)                           | 10.60 (0.05)                         | 10.60 (0.05)                         |
|                                      | 10.63 (0.05)                           | 10.68 (0.05)                         | 10.67 (0.06)                         |
|                                      | 10.56 (0.05)                           | 10.84 (0.05)                         | 0.05                                 |
|                                      | 10.69 (0.06)                           | 10.77 (0.07)                         | 0.004                                |

*: Other covariates include heart rate, total cholesterol, triglyceride, HDL-C, and LDL-C.

cfPWV is presented as mean (standard error).

doi:10.1371/journal.pone.0038485.t002
the tests for interactions with sex and BMI were not significant.

BMI, appeared to be more significant in women and in subjects with trend = 0.028 than those with low MAP (P for trend significant difference (p $\leq 0.05$) between the ‘absence’ and ‘presence’ groups of each marker.

doi:10.1371/journal.pone.0038485.g001

Figure 1. Geometric means of carotid-to-femoral pulse wave velocity (cfPWV, in m/s) by the presence of prediabetes status defined by IFG, IGT, and high HbA1c (5.7–6.4%). The analyses were adjusted for age, sex, BMI, MAP, heart rate and lipids (total cholesterol, triglyceride, HDL-C and LDL-C). Symbol '*' represents significant difference (p $\leq 0.05$) between the ‘absence’ and ‘presence’ of each marker.

doi:10.1371/journal.pone.0038485.g002

Figure 2. Geometric means of cfPWV (in m/s) by the combinations of high HbA1c (5.7–6.4%) with IFG and IGT. Symbol ‘-‘ represents the presence of the corresponding glucose exposures. The analyses were adjusted for age, sex, BMI, MAP, heart rate and lipids (total cholesterol, triglyceride, HDL-C and LDL-C). '*' represents significant difference (p $\leq 0.05$) comparing individuals with high HbA1c and IFG/IGT with the normal subjects (without any of these abnormalities); '**' represents significant difference (p $\leq 0.05$) comparing individuals with high HbA1c and IFG/IGT with those who had only high HbA1c and '*' represents significant difference (p $\leq 0.05$) comparing individuals with high HbA1c and IFG/IGT with those who had only IFG or IGT.

doi:10.1371/journal.pone.0038485.g003

Figure 3. The geometric means of cfPWV (in m/s) by according to HbA1c (in quintiles) by the presence/absence of high blood pressure defined by SBP $\geq 120$ mmHg and DBP $\geq 80$ mmHg. The analyses were adjusted for age, sex, BMI, heart rate and lipids.

doi:10.1371/journal.pone.0038485.g004

Discussion

In this study of a large sample of Chinese adults, long-term glycemic exposure, measured by HbA1c, was significantly associated with higher cfPWV, independent of other cardiovascular risk factors. We found that fasting glucose and 2 h OGTT showed additive effects with HbA1c on cfPWV. In addition, age and blood pressure significantly modified the associations between HbA1c and cfPWV.

Carotid-femoral pulse wave velocity, a gold-standard measure of intrinsic stiffness of the aortic wall, is an important predictor of cardiovascular disease risk [4,18,19]. Our findings are consistent with some previous studies. Matsumae et al. reported that HbA1c level was an independent determinant of cfPWV in hemodialysis patients with and without diabetes [9]. The association between HbA1c levels and increased arterial stiffness (measured by brachial-ankle pulse wave velocity [baPWV]) was recently observed in patients with type 2 diabetes [8]. Our data indicate that the long-term glucose exposure HbA1c may lead to increased arterial stiffness in non-diabetic individuals. The precise mechanisms how chronic glucose exposure may affect arterial stiffening are not fully understood. It was documented that BMI, blood pressure, heart rate, total cholesterol, LDL-C, HDL-C and triglyceride were related to cfPWV [15,16,20,21]. In our study, adjustment for these potential risk factors did not change the associations of HbA1c with cfPWV, suggesting that the effects of HbA1c are not mediated by these metabolic changes and likely to be through other independent pathways.

Individuals with prediabetes defined by the three measures of glucose exposure HbA1c, fasting glucose and 2 h OGTT all had significantly higher cfPWV. Our data indicate that, however, the changes in arterial stiffness were better associated with long-term glycemic exposure HbA1c than single measures of fasting glucose and 2 h OGTT on the continuous scales. Though highly correlated, these various measures for glucose exposure may convey different information regarding their relations with cardiovascular risk. Our data are consistent with previous studies in which HbA1c was a better predictor of cardiovascular disease than fasting glucose [22] and post-challenge glucose levels [23]. In addition, HbA1c has shown more consistent associations with retinopathy than fasting glucose level [2]. HbA1c value is a more stable biological index for long-term glycemia exposure than fasting glucose, which fluctuate within and between days and is therefore not a clear indicator of general glycemia.

Various mechanisms have been proposed to link glucose exposure with development of atherosclerosis. Long-term high
levels of circulating glucose lead to formation of advanced glycation endproducts (AGE), which result from non-enzymatic protein glycation forming irreversible cross-links in stable tissue proteins [24]. Matrix in the blood vessel wall is steadily reduced from exposure to AGE [25]. In addition, high AGE is known to impact endothelial function by quenching NO, enhancing the generation of reactive oxygen species (ROS), and induction of inflammation. All these alterations may contribute to development and progression of atherosclerosis [24,26]. It has been acknowledged that various glucose exposures are not perfectly concordant regarding their relations with disease outcomes [12]. Our study suggests that different measures of glucose exposure might have additive effects on arterial stiffness. Although these measures have been individually related to cardiovascular risk [8,10], the mechanisms underlying their joint effects are not unequivocally clarified. These various measures may reflect distinct abnormalities in glucose metabolism. High fasting glucose detects fasting hyperglycaemia, which is more typical of pancreatic β cell dysfunction; whereas high 2 h OGTT reveals post-prandial hyperglycaemia that is more closely associated with insulin resistance [27].

Table 3. Stratified associations between HbA1c and cfPWV (m/s) by sex, age and BMI.

| HbA1c in quintiles | P for trend | P for interaction |
|--------------------|-------------|-------------------|
| Q1 | Q2 | Q3 | Q4 | Q5 |
| Age |
| <40 y; N = 1143 | 10.03 (0.07) | 10.05 (0.09) | 9.93 (0.11) | 10.07 (0.14) | 10.26 (0.18) | 0.71 |
| 40 to 59 y; N = 2932 | 10.53 (0.07) | 10.60 (0.07) | 10.39 (0.07) | 10.47 (0.09) | 10.51 (0.09) | 0.59 |
| ≥60 y; N = 1023 | 12.40 (0.55) | 12.00 (0.55) | 12.91 (0.39) | 12.86 (0.40) | 13.50 (0.27) | 0.004 |
| Sex |
| Men, N = 2871 | 10.77 (0.07) | 10.90 (0.07) | 10.72 (0.07) | 10.86 (0.09) | 11.10 (0.09) | 0.06 0.88 |
| Women, N = 2227 | 9.85 (0.06) | 9.85 (0.06) | 9.85 (0.10) | 10.13 (0.13) | 10.05 (0.13) | 0.03 |
| BMI |
| <25 kg/m²; N = 2918 | 10.26 (0.06) | 10.42 (0.07) | 10.33 (0.08) | 10.39 (0.11) | 10.62 (0.12) | 0.025 0.42 |
| ≥25 kg/m²; N = 2180 | 10.82 (0.09) | 10.76 (0.10) | 10.66 (0.09) | 10.88 (0.10) | 10.92 (0.09) | 0.32 |

Analyses were adjusted for age, sex, BMI, total cholesterol, triglyceride, HDL-C, LDL-C, blood pressure, and heart rate but not the strata variable. cfPWV is presented as mean (standard error). doi:10.1371/journal.pone.0038485.t003

Acknowledgments

We thank all subjects for participating in this study.

Author Contributions

Conceived and designed the experiments: JL LQ. Performed the experiments: JL NZ FT CZ YX MY HS LQ. Analyzed the data: JL LQ. Contributed reagents/materials/analysis tools: JL LQ. Wrote the paper: JL LQ. Submitted the revised version of the manuscript and answered queries from editor and readers: JL LQ.
References

1. Szczepanska-Sadowska E, CardnoC J, Jedrzejewska A, Ufnal M, Zera T (2010) Brain and cardiovascular diseases: common neurogenic background of cardiovascular, metabolic and inflammatory diseases. J Physiol Pharmacol 61: 599–521.
2. Gillert M (2009) International Expert Committee report on the role of the A1C assay in the diagnosis of diabetes. Diabetes Care, 32: 1327–1334.
3. Laurent S, Cockcroft J, Van Boeijen L, Beutonyrie P, Giannattasio C, et al. (2006) Expert consensus document on arterial stiffness: methodological issues and clinical applications. Eur Heart J 27: 2548–2605.
4. Sutton-Tyrrell K, Najjar SS, Boudreau RM, Venkataraman L, Kupelian V, et al. (2005) Elevated aortic pulse wave velocity, a marker of arterial stiffness, predicts cardiovascular events in well-functioning older adults. Circulation 111: 3384–3390.
5. Blacher J, Aumar R, Djane S, London GM, Safar ME. (1999) Aortic pulse wave velocity as a marker of cardiovascular risk in hypertensive patients. Hypertension 33: 1111–1117.
6. Chae CU, Pfeffer MA, Glynn RJ, Mitchell GF, Taylor JO, et al. (1999) Increased pulse pressure and risk of heart failure in the elderly. JAMA 281: 634–639.
7. Cruickshank K, Riste L, Anderson SG, Wright JS, Dunn G, et al. (2002) Aortic pulse wave velocity: the Anglo-Cardiff Collaborative Trial (ACCT).
8. Chen Y, Huang Y, Li X, Xu M, Bi Y, et al. (2009) Association of arterial stiffness with HbA1c in 1,000 type 2 diabetic patients with or without hypertension. Endocrine 36: 262–267.
9. Matsukawa T, Abe Y, Murakami G, Ueda K, Saito T (2008) Effects of glucose metabolism on aortic pulse wave velocity in hemodialysis patients with and without diabetes. Hypertens Res 31: 1365–1372.
10. Cameron JD, Cruickshank JK (2007) Glucose, insulin, diabetes and mechanisms of arterial dysfunction. Clin Exp Pharmacol Physiol 34: 677–692.
11. Duyzer DA, Cohen JN (2007) Arterial stiffness as a risk factor for coronary atherosclerosis. Curr Atheroscler Rep 9: 139–144.
12. American Diabetes Association (2010) Diagnosis and classification of diabetes mellitus. Diabetes Care 33 Suppl 1: S62–69.
13. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus (1997) Diabetes Care, 20: 1183–1197.
14. McEnery CM, Yasmin, Hall IR, Qasem A, Wilkinson IB, et al. (2005) Normal vascular aging: differential effects on wave reflection and aortic pulse wave velocity: the Anglo-Cardiff Collaborative Trial (ACCT). J Am Coll Cardiol 46: 1753–1760.
15. Ciecelja M, Chwocienycz P (2009) Association of aortic pulse wave velocity with risk factors for cardiovascular disease other than hypertension: a systematic review. Hypertension 54: 1320–1336.
16. Wildman RP, Farhat GN, Patel AS, Mackey RH, Brockwell S, et al. (2005) Weight change is associated with change in arterial stiffness among healthy young adults. Hypertension 45: 187–192.
17. Wang Y, Wang QJ (2004) The prevalence of prehypertension and hypertension among US adults according to the new joint national committee guidelines: new challenges of the old problem. Arch Intern Med 164: 2126–2134.
18. Mitchell GF, Hwang SJ, Yassu RS, Larson MG, Pencina MJ, et al. (2010) Arterial stiffness and cardiovascular events: the Framingham Heart Study. Circulation 121: 505–511.
19. Meaume S, Benetos A, Henry OF, Rauchuchi A, Safar ME. (2001) Aortic pulse wave velocity predicts cardiovascular mortality in subjects >70 years of age. Arterioscler Thromb Vasc Biol 21: 2046–2050.
20. Wilkinson IB, Prasad K, Hall IR, Thomas A, MacCallum H, et al. (2002) Increased central pulse pressure and augmentation index in subjects with hypercholesterolemia. J Am Coll Cardiol 39: 1005–1011.
21. Benetos A, Warber B, Izzo J, Mitchell G, Resnick L, et al. (2002) Influence of age, risk factors, and cardiovascular and renal disease on arterial stiffness: clinical applications. Am J Hypertens 15: 1101–1108.
22. Selvin E, Steffes MW, Zhu H, Matsushita K, Wagenknecht L, et al. (2010) Glycated hemoglobin, diabetes, and cardiovascular risk in nondiabetic adults. N Engl J Med 362: 800–811.
23. Park S, Barrett-Connor E, Wingard DL, Shan J, Edelstein S (1996) GHb is a better predictor of cardiovascular disease than fasting or postchallenge plasma glucose in women without diabetes. The Rancho Bernardo Study. Diabetes Care 19: 450–456.
24. Shrivvany NA, Zou MH (2010) Arterial stiffness: a brief review. Acta Pharmacol Sin 31(10): 1267–1276.
25. Winlove CP, Parker KH, Avery NC, Bailey AJ (1996) Interactions of elastin and aorta with sugars in vitro and their effects on biochemical and physical properties. Diabetologia 39: 1131–1139.
26. Wendum T, Bucciarelli L, Qu W, Lu Y, Yan SF, et al. (2002) Receptor for advanced glycation endproducts (RAGE) and vascular inflammation: insights into the pathogenesis of macrovascular complications in diabetes. Curr Atheroscler Rep 4: 228–237.
27. Davies MJ, Raymond NT, Day JL, Hales CN, Burden AC (2000) Impaired glucose tolerance and fasting hyperglycaemia have different characteristics. Diabet Med 17: 433–440.
28. Mostafa SA, Davies MJ, Srinivasan BT, Carey ME, Webb D, et al. (2010) Should glycated haemoglobin (HbA1c) be used to detect people with type 2 diabetes mellitus and impaired glucose regulation? Postgrad Med J 86: 656–662.
29. Tomiyama H, Hashimoto H, Hirayama Y, Yambe M, Yamada J, et al. (2006) Synergistic acceleration of arterial stiffening in the presence of raised blood pressure and raised plasma glucose. Hypertension 47: 180–188.
30. Wang X, Desai K, Chang T, Wu L (2008) Vascular methylglyoxal metabolism and the development of hypertension. J Hypertens 25: 1565–1573.
31. Lapolla A, Mosca A, Fedele D (2011) The general use of glycated haemoglobin for the diagnosis of diabetes and other categories of glucose intolerance: still a long way to go. Nat Med Cardiovasc Dis 21: 467–473.